PhRMA Adds Its Opposition To Drug Negotiation Timeline Opposed By Generics

By John Wilkerson / November 17, 2021 at 7:25 PM
The brand drug industry is complaining about the drug-pricing deal’s Medicare price negotiation timeline that until recently only a few makers of biosimilars and generics complained about. However, the brand drug makers’ complaint is part of a tactic to kill the deal’s broader Medicare price negotiation provision, while makers of biosimilars and generics are lobbying to change the negotiation framework. Democrats’ pending reconciliation bill includes drug cost controls that would let Medicare negotiate prices after biopharmaceuticals have been on the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.